Attention deficit hyperactivity disorder

Astellas Closes California Facility; Takeda Expands ADHD Drug Production Amid Generic Competition

8 months ago talkbio0Tagged Astellas, Attention deficit hyperactivity disorder, competition, Facility (object), Reparative closure, Takeda, Vyvanse

Astellas, Takeda, ADHD drug, Vyvanse, generic competition, facility closure

FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###

11 months ago talkbio0Tagged Approved, Attention deficit hyperactivity disorder, clonidine, Extended Release Suspension, hydrochloride, Liquid medication, LiquiXR, Non-stimulant, Onyda, Pediatric brand name, Svalbard, Technology, Tris Pharma, United States Food and Drug Administration

Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology

Takeda Pharmaceuticals Revises Profit Forecast Due to Vyvanse Patent Expiration, Plans $900M Restructuring by 2024

12 months ago talkbio0Tagged Attention deficit hyperactivity disorder, Expiration, function, Legal patent, profit, restructuring, Takeda, Vyvanse

Takeda Pharmaceuticals, Vyvanse, patent expiration, profit outlook, restructuring, ADHD medication

Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports

1 year ago talkbio0Tagged Active shortages, Adderall, American Society of Health-System Pharmacists, Antineoplastic Agents, ASHP, Attention deficit hyperactivity disorder, Drug Enforcement Administration, Drug shortages, Drug supply chains, Generic sterile injectable medications, Policy, Recommendation, Record-high

Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations

US Drug Shortages Hit Record High Since 2001: ASHP Report

1 year ago talkbio0Tagged ASHP, Attention deficit hyperactivity disorder, Biden administration, Central Nervous System Stimulants, Chemotherapy Drugs Adminstered, controlled substance, Defense Production Act, DPA, Drug Enforcement Administration, Drug shortages, hormone agents, Hospitals, Incentives, intravenous fluids, Microbicides, Quality concerns, Record high, American Society of Health-System Pharmacists, shortage, Supply Chain Resilience, White House Council

Drug shortages, Record high, American Society of Health-System Pharmacists (ASHP), 323 drugs in shortage, Chemotherapy drugs, ADHD therapies, Central nervous system stimulants, Antimicrobials, Hormone agents, Intravenous fluids, Drug Enforcement Administration (DEA), Biden administration, White House Council on Supply Chain Resilience, Defense Production Act (DPA), Incentives for hospitals, Quality concerns, Controlled substances